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DOI 10.1016/j.ccr.2009.12.044SUMMARYMatrix metalloproteinase-9 (MMP-9) is the major MMP produced by B-CLL cells and contributes to their
tissue infiltration by degrading extracellular and membrane-anchored substrates. Here we describe
a different function for MMP-9 in B-CLL, which involves the hemopexin domain rather than its catalytic func-
tion. Binding of soluble or immobilized (pro)MMP-9, a catalytically inactive proMMP-9 mutant, or the MMP-9
hemopexin domain to its docking receptors a4b1 integrin and CD44v, induces an intracellular signaling
pathway that prevents B-CLL apoptosis. This pathway is induced in all B-CLL cases, is active in B-CLL
lymphoid tissues, and consists of Lyn activation, STAT3 phosphorylation, and Mcl-1 upregulation. Our
results establish that MMP/receptor binding induces intracellular survival signals and highlight the role of
(pro)MMP-9 in B-CLL pathogenesis.INTRODUCTION
Matrix metalloproteinase-9 (MMP-9; gelatinase B), a member of
the MMP enzyme family, is widely expressed in many tissues
and cell types, including those of lymphoid lineage (Opdenakker
et al., 2001; Stamenkovic, 2003; Deryugina and Quigley, 2006).
Like other members of the family, MMP-9 mainly degrades
components of the extracellular matrix, but it may also cleave
proteins involved in cell migration/invasion, apoptosis/cell sur-
vival, and angiogenesis as well as intracellular proteins. (Van
den Steen et al., 2002; Egeblad and Werb, 2002; Cauwe et al.,
2007; Xu et al., 2008). On the basis of extensive data from biolog-
ical, functional gene knockout, and clinicopathological studies on
enzyme activities, MMP-9 has been defined as an exquisite
target in inflammatory and vascular diseases (Hu et al., 2007).Significance
The local production of MMPs in the tumor environment by can
metastatic phenotypes and was a preamble for many studies
demonstrate that MMP-9 and specifically its hemopexin dom
mechanism. This finding not only constitutes a new mechani
cancer treatment but it also defines hemopexin domains as p
treatment.
160 Cancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc.MMP-9 is the major MMP found in certain B cell malignancies
such as B cell chronic lymphocytic leukemia (B-CLL). B-CLL
cells produce mostly 92 kDa proMMP-9 (Bauvois et al., 2002;
Redondo-Mun˜oz et al., 2006) and elevated intracellular levels
of this MMP correlate with advanced stage and poor patient
survival (Kamiguti et al., 2004), suggesting a role for MMP-9 in
B-CLL pathogenesis. B-CLL is characterized by the accumula-
tion in the peripheral blood (PB) of CD5+ B lymphocytes, which
progressively infiltrate the bone marrow (BM) and secondary
lymphoid tissues (Chiorazzi et al., 2005; Caligaris-Cappio and
Hamblin, 2008). B-CLL cells are resistant to apoptosis, and
several molecules including the chemokine receptors CXCR4
and CCR7, vascular endothelial factor receptors, and a4b1
integrin have been shown to participate in B-CLL cell migration
and to provide survival signals, thus contributing to B-CLLcer or bystander cells has been associated with invasive or
on inhibitors of MMP catalysis for cancer therapy. Here we
ain induce signals for B-CLL cell survival by a noncatalytic
sm to account for the failure of catalytic MMP inhibitors in
otential cancer targets and opens new directions for B-CLL
Figure 1. proMMP-9/Receptor Interaction Induces B-CLL Cell
Survival
(A) B-CLL cells (106/ml) were incubated on 96-well plates coated with 0.5%
BSA or the indicated concentrations of proMMP-9 for 48 hr. Cell viability
was determined by flow cytometry using Annexin V and propidium iodide.
Const. (constitutive) represents the average viability of fresh B-CLL cells.
(B) B-CLL cells at the indicated concentrations were incubated on BSA or
60 nM proMMP-9 for the indicated times and average viability values are
shown.
(C) B-CLL cells (106/ml) were cultured on BSA or the indicated proteins (all at
60 nM) and viability was measured after 48 hr.
(D) B-CLL cells with or without previous incubation with Abs or peptides were
added to BSA- or proMMP-9-coated wells and cell viability was determined
after 48 hr.
(E) B-CLL cells from the same subgroups shown in (C) were incubated
in suspension with the indicated proteins and viability was measured after
48 hr. Average values ± SD are shown. n indicates the number of patient
samples analyzed. *p% 0.05, **p% 0.01, ***p% 0.001. See also Figure S1.
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Fuente et al., 1999, 2002; Till et al., 2002, 2005). We and others
previously reported that pro and mature MMP-9 [(pro)MMP-9]
also play an important role in B-CLL transendothelial migration
and basement membrane invasion (Kamiguti et al., 2004;
Redondo-Mun˜oz et al., 2006, 2008a). Additionally, MMP-9 was
involved in the survival effect induced by B-CLL cell interaction
with BM stromal cells (Ringshausen et al., 2004). In both cases,
cell migration and cell survival, the effect of MMP-9 was due to
its proteolytic activity.
Although (pro)MMP-9 is a secreted protease and does not
bind to normal B cells (Redondo-Mun˜oz et al., 2008b), it has
been consistently detected at the B-CLL cell surface (Kamiguti
et al., 2004; Redondo-Mun˜oz et al., 2006, 2008b). Targeting
MMP-9 to the cell surface is mediated by specific docking recep-
tors and is thought to localize and enhance its proteolytic activity
at the pericellular space (Yu and Stamenkovic, 2000; Van den
Steen et al., 2002; Fridman et al., 2003). We have recently shown
that a4b1 integrin and a 190 kDa CD44 variant (CD44v) constitute
a docking complex for (pro)MMP-9 at the B-CLL cell surface
and that the MMP-9 hemopexin domain (PEX9) is required
for this interaction (Redondo-Mun˜oz et al., 2008b). Binding of
(pro)MMP-9 to this complex results in inhibition of B-CLL cell
migration and this again requires MMP-9 proteolytic activity.
These previous reports suggest an important role for cell-associ-
ated MMP-9 in the regulation of B-CLL cell migration and arrest.
In the present study, we have investigated whether cell-bound
MMP-9 may influence B-CLL cell survival and whether this
involves MMP-9 catalytic activity.
RESULTS
Adhesion to proMMP-9 or Binding of Soluble proMMP-9
Via a4b1 Integrin and CD44v Protects B-CLL Cells
Against Spontaneous Apoptosis
We studied whether purified proMMP-9 influenced the sponta-
neous apoptosis of cultured B-CLL cells. In initial experiments,
six B-CLL samples were cultured at 106 cells/ml on plates
coated with BSA or various concentrations of proMMP-9 and
viability was measured by flow cytometry after 48 hr. Figure 1A
shows that, starting at 27.5 nM, proMMP-9 significantly
increased B-CLL cell viability compared to BSA, reaching
a nearly maximal effect at 55 nM. A 55–60 nM concentration
was chosen for subsequent studies. To assess the time and
cell density dependence of proMMP-9 action, we studied cell
cultures for time intervals between 1 and 7 days and concentra-
tions ranging from 106 to 2 3 107 cells/ml. No differences
between BSA and proMMP9-treated cells were observed after
1 day for any of the conditions used (data not shown). However,
at day 2 (106 or 5 3 106/ml) or day 3 (107/ml [data not shown] or
2 3 107/ml), cells cultured on proMMP-9 showed significantly
higher viability than cells on BSA (Figure 1B). Thus, increasing
the cell density delayed the onset of apoptosis, but once this
started, proMMP-9 had a clear survival effect regardless of the
cell concentration. Although the viability of all tested cell cultures
decreased with time, a significant survival effect by proMMP-9
persisted for the 7 days of the assay for all conditions (Figure 1B).
For subsequent studies, 106 cells/ml concentration and 2 day
cultures were chosen.CTo determine whether the proMMP-9 survival function
affected all B-CLL cases or was specific for a selected subtype,
we analyzed B-CLL samples with mutated or unmutated IgVH
genes separately. We also studied a group of previously treated
B-CLL patients (Table 1), but with a prominent B-CLL cell popu-
lation. Figure 1C shows that all three subgroups showed signifi-
cantly higher viability (69.5%, 70%, and 62%, for unmutated,ancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc. 161
Table 1. Clinical Characteristics of B-CLL Patients
Patienta Sample Sex/Age Stageb CD38c ZAP70c Ig Statusc Therapy
P1 PB M/62 A + ND Unmutated None
P2 PB M/75 A + + Unmutated None
P3 PB M/77 A   Mutated None
P4 PB M/56 B/II   Mutated None
P5 PB M/63 B/II ND ND ND None
P6 PB F/84 A + ND Unmutated None
P7 PB M/64 B/II + ND ND None
P8 PB M/76 A + ND Mutated None
P9 PB M/36 A  ND ND None
P10 PB F/75 B/II + + ND None
P11 PB F/51 ND   Mutated None
P12 PB M/52 B/II + + Unmutated None
P13 PB F/75 A + + Mutated None
P14 PB M/60 A   Unmutated None
P15 PB F/44 A + + Unmutated None
P16 PB M/78 B/II  ND Mutated None
P17 PB F/71 A   Unmutated None
P18 PB M/67 B/II   Mutated None
P19 PB F/75 A + + Unmutated None
P20 PB F/66 B/II   Mutated None
P21 PB F/68 B/II +  Mutated None
P22 PB M/82 A + + Unmutated None
P23 PB M/72 A/II ND  Unmutated Fludara
P24 PB M/69 B/II  + Mutated Fludara + cyclophosphamide
P25 PB F/71 A/II + + Unmutated Leukeran
P26 PB F/68 B/II +  Mutated Fludara + cyclophosphamide
P27 PB M/78 B/II   Unmutated Fludara + cyclophosphamide
P28 PB M/72 C/IV +  Unmutated Leukeran + rituximab
P29 PB M/65 C/IV   Mutated Alemtuzumab
P30 PB + BM M/60 A/II   Mutated None
P31 PB + BM M/55 A/II + + Unmutated None
P32 PB + BM M/60 C/IV + + Mutated None
P33 PB + BM M/50 A/II   Unmutated None
P34 PB + LN M/57 A/II  + Mutated None
P35 PB + LN M/65 B/II + + Unmutated None
The following abbreviations are used: ND, not determined; PB, peripheral blood; BM, bone marrow; LN, lymph nodes.
a Because the described analyses were done for the whole group of patients (P), for specific subgroups, or for individual samples, in all figures patient
samples are indicated by the tabulated P numbers or by the total numbers (n =) from this cohort of 35 B-CLL patients.
b According to Rai et al. (1975) and Binet et al. (1981).
c The Ig status and the CD38 and ZAP70 expression in B-CLL cells has prognostic value (Chiorazzi et al., 2005; Caligaris-Cappio and Hamblin, 2008).
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proMMP-9 compared to their respective counterparts cultured
on BSA (41%, 42%, and 34%). A similar significant (p% 0.001)
anti-apoptotic effect was observed on cells attached to
recombinant full-length proMMP-9 (rproMMP-9; Figure 1C).
Comparison of ZAP70+/CD38+ (five samples) versus ZAP70/
CD38 (six samples) also rendered similar results (data not
shown). To confirm these results we also measured cell viability
by the MTT method. Parallel determinations with Annexin V/
propidium iodide or MTT on six B-CLL samples (three with162 Cancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc.unmutated and three with mutated IgVH) rendered identical
results by both methods (Figures S1A and S1B, available online).
Moreover, no cell proliferation was observed on these cultures,
measured by cell counting and cycle analyses with propidium
iodide (data not shown).
To establish whether MMP-9 proteolytic activity was involved
in this survival function, we studied the effect of a rproMMP-9
protein carrying a mutation in the catalytic site (rproMMP-
9MutE) and devoid of catalytic activity (Van den Steen et al.,
2006). We previously showed that B-CLL cells attach to this
Cancer Cell
Noncatalytic B-CLL Cell Survival Function for MMP-9mutant as effectively as to rproMMP-9 or natural proMMP-9
(Redondo-Mun˜oz et al., 2008b). As shown in Figure 1C,
rproMMP-9MutE also protected B-CLL cells from spontaneous
apoptosis, regardless of their IgVH mutational stage or the
receipt of treatment. Moreover, blocking MMP-9 activity by
previous incubation with its inhibitor TIMP-1 did not affect the
observed anti-apoptotic effect (Figure 1C). In agreement with
this, cell adhesion to activated 83 kDa MMP-9 rendered similar
viability levels as adhesion to proMMP-9 and, as observed for
the proform, this effect was not abolished by TIMP-1 (Figure 1C).
To further confirm these results we studied the effect of several
proMMP-9 truncated variants on B-CLL cell viability. Figure 1C
shows that the mouse MMP-9 hemopexin domain (PEX9)
(Roeb et al., 2002) also induced cell survival of all B-CLL samples
and to a similar level as human proMMP-9. Removal of the PEX9
domain and/or the adjacent O-glycosylated region abolished cell
adhesion to proMMP-9 (data not shown; Redondo-Mun˜oz et al.,
2008b) and the anti-apoptotic effect (Figure 1C). To establish
whether this function was unique for PEX9 or shared by other
MMP hemopexin domains, we analyzed the effect of the human
MMP-2 hemopexin region (PEX2). Culturing B-CLL cells (n = 8
patients, 5 with mutated and 3 with unmutated IgVH) on PEX2
for 48 hr resulted in significantly higher viability (66%) than
culturing these on BSA (40%; data not shown), suggesting that
the ability to induce cell survival may be a common property of
MMP hemopexin domains.
To confirm that proMMP-9-induced viability was due to inter-
action with its surface receptors, a4b1 integrin and CD44v, we
blocked a4b1 with the HP2/1 mAb or the CS-1 synthetic peptide
or CD44 with specific Abs. These treatments prevented adhe-
sion to proMMP-9 (data not shown) and the subsequent anti-
apoptotic function, whereas the control anti-a4 mAb HP1/7 or
the CS-3 peptide had no effect (Figure 1D).
Because proMMP-9 is a secreted protease, we next studied
whether soluble proMMP-9 also produced a survival effect.
B-CLL cells (same subgroups as in Figure 1C) were incubated
in suspension with or without proMMP-9 and viability was
measured after 48 hr. FACS analyses confirmed that proMMP-9
remained bound to the B-CLL cell surface at this time (Fig-
ure S1C) and this resulted in significantly higher cell viability
compared to control cells (Figure 1E). As observed for immobi-
lized proMMP-9, soluble rproMMP-9MutE or (pro)MMP-9 com-
plexed with TIMP-1 also increased B-CLL viability (Figure 1E).
Altogether these results established that binding of proMMP-9
to its docking receptors is necessary for prevention of apoptosis
and that the antiapoptotic effect does not require MMP-9
proteolytic activity.
Cell Adhesion to proMMP-9 Upregulates Mcl-1 and
PreventsMitochondrial DamageandCaspaseActivation
To analyze the antiapoptotic mechanism induced by proMMP-9,
we first studied the possible involvement of Bcl-2 protein
family members. B-CLL cells (n = 3) were incubated on BSA
or proMMP-9 and after 48 hr were lysed and analyzed by western
blotting. Figure 2A shows that Mcl-1, but not Bcl-xL or the Bcl-2/
Bax ratio, was upregulated in all samples cultured on proMMP-9
(average 3.6-fold increases of Mcl-1 compared to constitutive
values), but not on their corresponding BSA cultures. Mcl-1
protein degradation was not observed in these assays. Mcl-1Clevels already increased 2.9-fold after 24 hr, in spite of a similar
viability at this time between proMMP-9 and BSA cultures
(Figure S2A). Soluble proMMP-9 and the immobilized PEX9 and
PEX2 domains also specifically induced Mcl-1 upregulation
(Figures S2B and S2C). Moreover, Mcl-1 mRNA was also signif-
icantly (p % 0.001) induced in B-CLL cells cultured for 2 hr
on proMMP-9, compared to BSA-cultured cells (Figure 2B).
Elevated Mcl-1 mRNA levels were maintained for at least 24 hr
(data not shown). Addition of actinomycin D after the 2 hr culture
followed by RT-PCR analysis at various time points revealed that
proMMP-9 did not induceMcl-1mRNA stabilization (Figure S2D).
These results established that proMMP-9 regulated Mcl-1 at the
transcriptional level.
We next studied the role of Mcl-1 in the antiapoptotic pathway
elicited by proMMP-9. Figure 2C shows that anti-Mcl-1 Abs
pulled down the BH3-only proapoptotic protein Bim from lysates
of proMMP-9 but not BSA-cultured B-CLL cells. This indicated
that, in response to proMMP-9, Mcl-1 sequestered BH3-only
proteins thus preventing mitochondrial damage and apoptosis.
To confirm this, we studied cytochrome c release by immunoflu-
orescence, using the mitochondrial protein Hsp60 as reference.
Figure 2D shows, for a representative sample, that after 24 hr
culture on BSA, a lack of colocalization of cytochrome c and
Hsp60 was already visible and became very evident after
48 hr, confirming its mitochondrial release. In contrast, colocali-
zation of both proteins was clearly observed on proMMP-9-
cultured cells. Accordingly, active Bax, a proapoptotic factor
involved in the mitochondrial pathway, was readily detected
after 24 hr on BSA-treated cells, but it was mostly absent on
proMMP-9-treated cells (Figure 2D). Cytochrome c release
was not affected by the caspase inhibitors ZVAD-FMK or
Z-IETD-FMK (Figure S2E), indicating that it preceded caspase
activation. Hence, caspase-3 activation was not observed in
24 hr cultures (data not shown). However, after 48 hr, caspase-3
was converted to the active 17 kDa form and cleaved its
substrate PARP-1 on cells cultured on BSA but not on
proMMP-9 (Figure S2F). Caspase-8 activation and degradation
of its substrate Bid was also observed on 48 hr BSA cultures,
probably due to an apoptosis amplification loop (Garrido et al.,
2006). In support of this, the caspase-8 inhibitor Flip was not
modulated under BSA or proMMP-9 culture conditions (Fig-
ure S2F). Altogether these results indicated that spontaneous
apoptosis of B-CLL cells on BSA involved the mitochondrial
pathway and initiation of this mechanism was prevented by
proMMP-9.
To determine whether Mcl-1 upregulation was required for the
proMMP-9 survival effect, we transfected B-CLL cells with two
different Mcl-1 siRNAs. Western blotting analyses confirmed
that both siRNA efficiently reduced Mcl-1 expression (average
58% and 71% reduction for siRNA1 and siRNA2, respectively),
with respect to untransfected or control siRNA-transfected cells
(Figure 2E). siRNA transfection did not significantly affect cell
adhesion to proMMP-9 (or VCAM-1, used as control) (Fig-
ure S2G).Mcl-1 gene silencing did not reduce the viability of cells
on BSA but resulted in complete inhibition of the proMMP-9 anti-
apoptotic effect, with viability values falling from 72%–70%
(untransfected and control siRNA-transfected cells, respectively)
to 52% and 50% for Mcl-1 siRNA1 and siRNA2 respectively
(Figure 2F). This was accompanied by activation of caspase-3ancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc. 163
Figure 2. Cell Adhesion to proMMP-9
UpregulatesMcl-1 Expression and Prevents
Mitochondrial Damage
(A) A total of 3 3 106 B-CLL cells from three
different patients were lysed before (Const.) or
after 48 hr culture on 0.5% BSA- or 60 nM
proMMP-9-coated plates and analyzed by
western blotting. Values represent the average
Bcl-2 family protein/actin ratio after normalizing
constitutive values to 1.
(B) 107 B-CLL cells were cultured on BSA or
proMMP-9 for 2 hr and Mcl-1 mRNA expression
was analyzed by RT-PCR. Normalized average
values are shown.
(C) Lysates from 2 3 107 B-CLL cells cultured for
48 hr on BSA or proMMP-9 were immunoprecipi-
tated with anti-Mcl-1 Abs or rabbit IgG (Ctl) and
analyzed by western blotting.
(D) B-CLL cells cultured on BSA or proMMP-9 for
24 or 48 hr were analyzed by confocal microscopy
using Abs for cytochrome c or active Bax, followed
by Alexa488-labeled secondary Abs. Hsp60 was
detected with specific Abs and Texas red-labeled
secondary Abs. Colocalization of cytochrome c
and Hsp60 was further demonstrated by dot-plot
analyses. Scale bar, 10 mm.
(E) B-CLL cells were transfected or not with the
indicated siRNAs and analyzed by western blot-
ting. Representative blots from four samples
are shown. Numbers represent the average (six
samples) Mcl-1/actin ratio after normalizing
untransfected cell values to 1.
(F) The same samples shown in (E) were cultured
on BSA or proMMP-9 and viability was determined
after 48 hr by flow cytometry. Average values ± SD
are shown. ***p% 0.001. See also Figure S2.
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that Mcl-1 was a crucial component of the proMMP-9 survival
effect.
The Src Family Kinase Lyn Is Responsible
for the proMMP-9 Antiapoptotic Function
To determine the signaling pathway involved in the proMMP-9
survival function, we first cultured B-CLL cells on BSA or
proMMP-9 in the absence or presence of specific kinase inhibi-
tors and measured their viability after 48 hr. Figure 3A shows that
blocking PI3K/Akt, MEK, p38 MAPK, or PKC signaling did not
prevent the antiapoptotic activity of proMMP-9. However, block-
ing Src family kinase (SFK) signaling with PP2 or dasatinib164 Cancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc.reduced the viability of cells on
proMMP-9 to the levels of cells on BSA;
PP3, an inactive analog of PP2, had no
effect. Consequently, in the presence of
PP2 or dasatinib, but not of PP3 or the
B cell receptor (BCR) inhibitor nilotinib,
Mcl-1 was not upregulated by proMMP-9
(Figure 3B) and cells were no longer pro-
tected against caspase activation (Fig-
ure S3A). We next aimed to identify the
SFK responsible for the observed survival
signaling. B-CLL cells mainly express theLyn and Lck members of this family (Majolini et al., 1998) and we
confirmed the presence of these two kinases in lysates of two
representative B-CLL samples (Figure S3B). As signaling was
induced upon proMMP-9 binding to a4b1 integrin and CD44v
(Figure 1D), we next studied whether Lyn or Lck constitutively in-
teracted with these receptors. Lysates from fresh B-CLL cells
were immunoprecipitated with anti-b1 or anti-CD44 Abs and
analyzed by western blotting. Figure 3C shows that anti-b1
Abs pulled down the b1 and a4 integrin subunits as expected,
plus one band of 55 kDa, which was recognized by anti-Lyn
but not by anti-Lck Abs. Lyn was absent in the anti-CD44 immu-
noprecipitates (data not shown), indicating the specific asso-
ciation of this kinase with a4b1 integrin. Conversely, western
Figure 3. Lyn Kinase Signaling Is Involved in proMMP-9-Induced Cell Survival and Mcl-1 Upregulation
(A) B-CLL cells were incubated on BSA- or proMMP-9-coated wells in the presence or absence of the indicated inhibitors and viability was measured after 48 hr
by flow cytometry.
(B) B-CLL cells treated or not with the indicated inhibitors were added to BSA- or proMMP-9-coated wells. After 48 hr cells were lysed and Mcl-1 was analyzed by
western blotting. Numbers represent normalized average Mcl-1/actin values.
(C) Lysates from fresh B-CLL cells were immunoprecipitated with anti-b1 integrin subunit mAbs and analyzed by western blotting.
(D) B-CLL cells were lysed before or after 30 min culture on BSA- or proMMP-9-coated plates. Lysates were immunoprecipitated with anti-Lyn pAbs and analyzed
by western blotting.
(E) A total of 33 106 B-CLL cells, cultured on BSA or proMMP-9 for the indicated times, were lysed and protein phosphorylation was analyzed by western blotting.
Representative blots for two patient samples and average values for six samples are shown.
(F) A total of 23 106 B-CLL cells were transfected or not with the indicated siRNAs and the efficiency of the transfection was analyzed by western blotting. Normal-
ized average values (n = 6) are shown.
(G) The same cell samples used in (F) were cultured on BSA or proMMP-9 for 48 hr, lysed, and analyzed for Mcl-1 expression by western blotting. Normalized
average values ± SD are shown.
(H) An aliquot of the cells used in (G) was removed before lysis and viability was determined by flow cytometry. *p% 0.05, ***p% 0.001. See also Figure S3.
Cancer Cell
Noncatalytic B-CLL Cell Survival Function for MMP-9blotting analyses of anti-Lyn immunoprecipitates revealed the
presence of the a4 and b1 integrin subunits (Figure S3C). These
results were further confirmed by immunofluorescence analyses
using confocal microscopy. Figure S3D shows that for a repre-
sentative sample the a4/b1 subunits, but not CD44, colocalized
with Lyn at the cell periphery, as documented by dot-plot
analysis.
The preceding experiments clearly established that Lyn was
bound to a4b1 integrin in unstimulated B-CLL cells. We next
studied whether a4b1/proMMP-9 interaction affected this bind-
ing and/or activated Lyn. Lysates of cells that had been incu-
bated on BSA or proMMP-9 for 30 min were immunoprecipitatedCwith anti-Lyn Abs and analyzed by western blotting. Figure 3D
shows that after cell incubation on BSA, the b1 integrin subunit
remained bound to Lyn, but this association was almost
completely lost upon incubation on proMMP-9. To determine
whether this was due to Lyn activation, we incubated the same
lysates with anti-p-Lyn Tyr396 Ab and analyzed them by western
blotting. Indeed, cell binding to proMMP-9 clearly resulted in Lyn
Tyr396 phosphorylation while incubation on BSA did not
(Figure 3D). In agreement with this, the Lyn substrates HS1
and SHIP1 were phosphorylated on proMMP-9-cultured cells
in correlation with Lyn activation (Figure 3E). Both substrates
as well as Lyn were already phosphorylated after 15 min (dataancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc. 165
Figure 4. Cell Adhesion to proMMP-9
Induces STAT3 Phosphorylation and Bind-
ing to the Mcl-1 Promoter in a Lyn-Depen-
dent Manner
(A) B-CLL cells were lysed before (Const.) or after
culture on BSA- or proMMP-9-coated plates.
STAT3 and STAT5 phosphorylation was analyzed
by western blotting and average values (n = 4)
are shown.
(B)B-CLL cells transfectedornotwithLynorcontrol
siRNAs were cultured on BSA or proMMP-9 for 1 hr,
lysed, and analyzed by western blotting.
(C) B-CLL cells were cultured on BSA or proMMP-9
for 2 hr and the nuclear and cytosolic fractions were
separated. Nuclear extracts were incubated with
the indicated biotinylated DNA probes and strepta-
vidinparticles and analyzedbywestern blotting.The
H4 histone was used as an internal nuclear marker.
(D) B-CLL cells were transfected or not with the indi-
cated siRNAs and, after 24 hr, cells were lysed and
analyzed by western blotting.
(E) Individual B-CLL cells from four patients trans-
fected or not with STAT3 or control siRNA were
cultured on BSA or proMMP-9 for 2 hr. Cells were
collectedandMcl-1mRNAexpressionwasanalyzed
by RT-PCR using GAPDH as internal control.
(F) The viability of untransfected and siRNA-trans-
fected B-CLL cells after 48 hr culture on BSA or
proMMP-9 was determined by flow cytometry.
Average values ± SD are shown. *p % 0.05,
***p% 0.001. See also Figure S4.
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60 min (SHIP1) of proMMP-9 exposure (Figure 3E). As observed
for Mcl-1 (Figure 3B), the BCR inhibitors imatinib and nilotinib did
not affect proMMP-9-induced Lyn phosphorylation, although
this was abolished by PP2 or dasatinib (Figure S3E). Likewise,
the BCR inhibitors (or a Janus kinase-2 inhibitor; data not shown)
did not affect the increased viability of proMMP-cultured cells at
any of the concentrations tested (Figure S3F).
Having established that Lyn was specifically activated by
proMMP-9, we studied whether Lyn was necessary for the
observed survival effect. B-CLL cells (n = 6) were transfected
with two different Lyn siRNAs and analyzed for Mcl-1 expression
and cell viability. Figure 3F shows that both siRNAs significantly
reduced Lyn expression (average 72% and 75%, respectively),
compared to untransfected or control siRNA-transfected cells.166 Cancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc.Lyngene silencing did not affect cell adhe-
sion to proMMP-9 (Figure S3G), but abol-
ished HS1 phosphorylation (Figure S3H),
Mcl-1 upregulation (Figure 3G), and the
anti-apoptotic effect induced by cell
binding to proMMP-9 (Figure 3H). This
effect was specific, as cells transfected
with control siRNA and incubated on
proMMP-9 displayed a significantly higher
viability than when incubated on BSA
(Figure 3H). Lyn gene silencing did not
increase the spontaneous apoptosis of
cells on BSA (Figure 3H). These resultsclearly established that Lyn plays a key role in the anti-apoptotic
signaling induced by cell adhesion to proMMP-9.
B-CLL Cell Adhesion to proMMP-9 Induces STAT3
Phosphorylation in a Lyn-Dependent Manner
To further explore the signaling pathway initiated by proMMP-9
and leading to Lyn activation and Mcl-1 upregulation, we studied
the transcription factors involved. SFK have been shown to
phosphorylate STAT factors (Silva, 2004; Hayakawa and Naoe,
2006), and STAT3 and STAT5 can regulate Mcl-1 expression
(Akgul, 2009). We therefore analyzed whether STAT3 and
STAT5 were phosphorylated upon cell adhesion to proMMP-9.
STAT3 phosphorylation was appreciable after 30 min of
adhesion (data not shown) and was maximal (2.1-fold increase,
p % 0.01) after 1 hr (Figure 4A), whereas STAT5 was not
Figure 5. B-CLL Cells Cultured on Primary
Stromal Cells or Isolated from Lymphoid
Tissues Show Increased Surface-Bound
MMP-9, p-Lyn, and Mcl-1 and Viability
(A) B-CLL cells from five patients were individually
cultured on BSA or primary stromal cells for 48 hr
in the presence or absence of the indicated Abs.
Cell viability was determined by flow cytometry
and average values are shown.
(B) B-CLL cells from three of the samples used in
(A) were lysed after 30 min (p-Lyn) or 48 hr
(Mcl-1) culture on BSA or stromal cells (Str.) and
analyzed by western blotting. Normalized average
values are shown.
(C and D) Fresh B-CLL cells from the BM and PB
(n = 4) (C) or LN and PB (n = 2) (D) of the same
patient, were incubated (30 min, 4C) with or
without 60 nM of soluble proMMP-9. Cells were
treated with an anti-MMP-9 Ab and secondary
Abs and analyzed by flow cytometry. Shaded areas
represent constitutive expression and dotted lines
indicate exogenous proMMP-9 bound. Average
values after normalizing PB constitutive expression
to 1 are shown.
(E and F) B-CLL cells isolated from BM and PB
(E) or LN and PB (F) were lysed and analyzed by
western blotting. pLyn/actin and Mcl-1/actin
average values were obtained after normalizing
PB values to 1. Error bars represent SD. *p %
0.05, **p% 0.01, ***p% 0.001. See also Figure S5.
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lation followed similar kinetics (Figures 3E and 4A). STAT3
phosphorylation persisted after 3 hr (Figure 4A) and was no
longer visible after 6 hr (data not shown). The Lyn kinase was
required for STAT3 activation, as it was abolished by Lyn gene
silencing (Figure 4B). Next, to establish that STAT3 activation
was responsible for the increased Mcl-1 mRNA transcription
(Figure 2B), we analyzed whether STAT3 bound to the Mcl-1
promoter. Nuclear extracts from B-CLL cells that had been
cultured for 2 hr on BSA or proMMP-9 were incubated with bio-
tinylated DNA probe and streptavidin-labeled beads and
analyzed by western blotting. STAT3 was clearly increased in
the nuclear fraction of proMMP-9-treated cells compared to
BSA-treated cells (Figure 4C). Moreover, STAT3 fromCancer Cell 17, 160–172,proMMP-9-cultured cells was specifically
pulled down by a Mcl-1 promoter probe,
but not by a mutated or control DNA
probe (Figure 4C). These results clearly
indicated that STAT3 was responsible
for the Mcl-1 upregulation induced
by proMMP-9. Accordingly, transfection
with STAT3 siRNAs (Figure 4D) abolished
Mcl-1 mRNA upregulation (Figure 4E)
and the proMMP-9 survival effect (Fig-
ure 4F), without affecting cell adhesion
to proMMP-9 (Figure S4). Altogether
these results established that proMMP-9/
receptor ligation in B-CLL cells initiates
a signaling pathway involving Lyn andSTAT3 activation that results in Mcl-1 upregulation and cell
survival.
B-CLL Cells Present in Lymphoid Organs Display Higher
Surface MMP-9 Expression, Lyn Activation, and Mcl-1
Levels than Their Peripheral Blood Counterparts
We next studied whether the outlined survival pathway was
observed in the pathophysiological context of B-CLL. As a first
approach, B-CLL cells were co-cultured with primary stromal
cells derived froma B-CLL patient, and the viability was measured
after 48 hr. Under these conditions B-CLL cells had significantly
higher viability than BSA-cultured cells (Figure 5A), confirming
previous reports (Lagneaux et al., 1998; Ringshausen et al.,
2004). The survival effect was inhibited by anti-a4 integrin subunitFebruary 17, 2010 ª2010 Elsevier Inc. 167
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both molecules. Importantly, B-CLL cell surface MMP-9 expres-
sion increased >2-fold upon stromal cell contact (Figure S5A).
Furthermore, analyses of lysates of B-CLL cells that had been
in contact with stromal cells revealed significant upregulation of
p-Lyn and Mcl-1, compared to BSA cell cultures (Figure 5B).
We then reasoned that B-CLL cells, when present in lymphoid
organs, upregulate their surface MMP-9 expression (by binding
endogenous and/or exogenous MMP-9) and activate the survival
pathway. To address this, B-CLL cells were isolated from the PB
and BM (n = 4) or PB and lymph nodes (LN; n = 2) of individual
patients and their MMP-9 expression was analyzed by flow
cytometry. Figures 5C and 5D show that BM and LN B-CLL cells
constitutively expressed more surface MMP-9 (average 1.8-fold,
p% 0.001, and 2.6-fold, p% 0.01, for BM and LN, respectively)
than their PB counterparts. Accordingly, PB cells were able to
bind exogenously added proMMP-9, increasing its surface
expression by >2-fold. BM or LN cells, however, only raised
this expression by 1.2-fold (Figures 5C and 5D). In agreement
with an elevated MMP-9 expression, BM and LN cells had signif-
icantly higher constitutive levels of p-Lyn and Mcl-1 than PB cells
(Figures 5E and 5F). Consequently, and although the constitutive
viability of PB and BM (or LN) cells was similar, after 48 hr culture
BM cells showed increased viability compared to PB cells (65%
versus 41%, p% 0.05) (Figure S5B). These results clearly estab-
lished that B-CLL cells increase their surface MMP-9 in lymphoid
tissues and that the outlined proMMP-9 survival pathway is
active in B-CLL.
Comparison between the Survival Pathways Triggered
by proMMP-9 and VCAM-1 Reveals Different Signaling
by Two a4b1 Integrin Ligands
We and others previously showed that cell adhesion to VCAM-1
via a4b1 integrin prevents spontaneous apoptosis of B-CLL cells
(Lagneaux et al., 1998; De la Fuente et al., 1999). We therefore
studied if VCAM-1 induced the same survival pathway as
proMMP-9. B-CLL cells were incubated on VCAM-1 in the pres-
ence or absence of PI3-K, SFK, or ERK1/2 inhibitors, and cell
viability was determined after 48 hr. In the absence of inhibitors,
VCAM-1 had a similar anti-apoptotic effect (68% average
viability) (Figure 6A) as proMMP-9 (Figures 1C–1E). At difference
with the proMMP-9 induced signaling, blocking PI3-K with
LY294002 reduced the viability of cells attached to VCAM-1 to
48.2%, while the SFK inhibitors dasatinib and PP2 did not
(Figure 6A). The inactive analog PP3 or the ERK1/2 inhibitor
UO126 had no effect (Figure 6A). In agreement with these results,
adhesion of B-CLL cells to VCAM-1 resulted in phosphorylation
of Akt but not of Lyn, while adhesion to proMMP-9 induced Lyn
phosphorylation as expected, without activating Akt (Figure 6B).
We next studied whether cell adhesion to VCAM-1 upregu-
lated Mcl-1. Figure 6C shows that Mcl-1 expression was not
upregulated by cell adhesion to VCAM-1 and, consequently,
Mcl-1 gene silencing did not affect the VCAM-1-induced anti-
apoptotic effect (Figure 6D). In contrast, Bcl-xL, which was not
modulated upon adhesion to proMMP-9 (Figure 2A), was signif-
icantly induced (1.8-fold) by VCAM-1 (Figure 6C).
To determine whether both survival pathways cooperated, we
incubated B-CLL cells on proMMP-9, VCAM-1, or both and
measured the viability after 48 hr. Figure 6E shows that cells168 Cancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc.cultured in mixed substrata had similar viability than when
cultured on proMMP-9 or VCAM-1 alone, ruling out a cooperative
effect. Upregulation of Bcl-xL and Mcl-1 on mixed substrata was
significant, but was lower than when triggered by each protein
alone (Figure 6F), suggesting a possible competition between
both pathways. Altogether these results established that the
survival pathway induced by proMMP-9 was clearly different
from that elicited by VCAM-1, albeit both proteins are ligands
for a4b1 integrin. A schematic representation of both pathways
is shown in Figure 7.
DISCUSSION
We have studied the functional consequences of proMMP-9
binding to its receptors, a4b1 integrin and CD44v, in B-CLL cells.
We report that proMMP-9, either immobilized or in soluble form,
induced an intracellular signaling pathway leading to cell
survival. An anti-apoptotic role for MMP-9 has been previously
observed in several experimental models of carcinoma (Meyer
et al., 2005; Acuff et al., 2006; Kunigal et al., 2008). MMP-9
also contributed to the survival of B-CLL cells on BM stroma
(Ringshausen et al., 2004). In these previous studies, the
MMP-9 antiapoptotic effect was due to its enzymatic activity.
The present study shows that the sole engagement of
proMMP-9 or the hemopexin domains of MMP-9 or MMP-2 to
its cell surface receptors induced cell survival signals. This repre-
sents a surprising function for an MMP, which does not require
its proteolytic activity. Our data also add induction of signal
transduction as a new function to the known multifunctional
liganding activities of MMP hemopexin domains (Piccard et al.,
2007). Whether this property is shared by all hemopexin-contain-
ing proteins remains to be established.
The Lyn kinase was a specific and crucial component of the
signaling pathway elicited by proMMP-9/receptor interaction.
Lyn is constitutively active in B-CLL cells and contributes to their
defective apoptosis, as inhibiting this kinase with PP2 (Contri
et al., 2005) or dasatinib (Veldurthy et al., 2008), or disruption
of an aberrant Lyn/Hsp90 cytosolic complex (Trentin et al.,
2008) induced cell death. We show in this report that Lyn was
further activated in response to proMMP-9 and this contrasts
with the poor Lyn activity increase induced by BCR engagement
in B-CLL cells (Contri et al., 2005). Instead, BCR upregulated
Mcl-1 and induced cell survival mostly via PI3K/Akt and
ERK activation (Petlickovski et al., 2005; Longo et al., 2008).
Activation of Lyn by proMMP-9 therefore represents a distinct
and BCR-independent mechanism contributing to B-CLL cell
survival. Moreover, Lyn was responsible for the subsequent
STAT3 phosphorylation and Mcl-1 upregulation. Phosphoryla-
tion of STATs by SFK members is an alternative mechanism
independent of the canonical JAK-STAT pathway (Silva, 2004;
Hayakawa and Naoe, 2006). Nevertheless, the possibility of
Lyn acting via an intermediate factor cannot be disregarded.
Like in the case of Lyn, both STAT3 and Mcl-1 were crucial
and specific components of the proMMP-9-induced survival
signaling.
The described antiapoptotic pathway required B-CLL cell
solid-phase adhesion or binding in solution to proMMP-9. We
have previously shown that a4b1 integrin and CD44v are involved
in this interaction (Redondo-Mun˜oz et al., 2008b). Our present
Figure 6. B-CLL Cell Adhesion to VCAM-1
Induces a Survival Pathway that Is Different
from that Induced by proMMP-9
(A) B-CLL cells from three patients were treated or
not with the indicated kinase inhibitors and added
to BSA- or 60 nM VCAM-1-coated wells. After
48 hr, cell viability was determined and average
values are shown.
(B) B-CLL cells were lysed before or after 30 min
culture on BSA, proMMP-9, or VCAM-1 and Lyn
and Akt activation was analyzed by western
blotting.
(C) B-CLL cells before or after 48 hr culture on
BSA- or VCAM-1-coated wells were lysed and
Bcl-2 family proteins were analyzed by western
blotting. Quantitative values represent the Bcl-2
family protein/actin ratio after normalizing consti-
tutive values to 1.
(D) B-CLL cells from six patients transfected or not
with the indicated siRNAs were cultured on BSA or
VCAM-1 and viability was measured after 48 hr by
flow cytometry.
(E) B-CLL cells from six patients were cultured on
the indicated proteins for 48 hr and viability was
determined by flow cytometry.
(F) B-CLL cells from four patients were cultured on
the indicated proteins for 48 hr, lysed, and
analyzed by western blotting. Normalized average
values ± SD are shown. *p % 0.05, **p % 0.01,
***p% 0.001.
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CD44v may stabilize or strengthen this interaction. Contribution
of a4b1 integrin to B-CLL cell viability and resistance to
fludarabine was previously demonstrated upon adhesion to
fibronectin, VCAM-1, or BM stromal cells (Lagneaux et al.,
1998; De la Fuente et al., 1999, 2002). We now show that induc-
tion of cell survival by the a4b1/VCAM-1 axis does not involve the
Lyn/STAT3/Mcl-1 pathway, which thus appears to be unique for
proMMP-9. This indicates that a4b1 integrin may trigger distinct
intracellular events depending on the engaged ligand. Accord-
ingly,a4b1-mediated T lymphocyte adhesion to VCAM-1 or fibro-
nectin was shown to differentially upregulate MMP-2 or MMP-2/
MMP-9 mRNA, respectively (Yakubenko et al., 2000). As our
present results further demonstrate that the VCAM-1 andCancer Cell 17, 160–172,proMMP-9 survival pathways show
a certain degree of competition, the avail-
ability (or higher expression) of each
ligand at a given location probably deter-
mines the signals induced.
The present report therefore estab-
lishes that proMMP-9 is a functional
ligand for a4b1 integrin, able to induce
intracellular signals independently of its
proteolytic activity. Although B-CLL cells
synthesize and bind proMMP-9 (Bauvois
et al., 2002; Kamiguti et al., 2004;
Redondo-Mun˜oz et al., 2006, 2008b) our
results show that this may not be suffi-
cient to induce the survival pathway, as
in the absence of exogenous proMMP-9, cells become apoptotic after 2 days in culture. Increasing
evidence supports the notion that the microenvironment plays
an essential role in the proliferation and resistance to apoptosis
of B-CLL cells. In vitro experiments have demonstrated that
culturing B-CLL cells on several cell types increases B-CLL
cell viability (Burger et al., 2000; Lagneaux et al., 1998; Panayio-
tidis et al., 1996; Pedersen et al., 2002), strongly suggesting that
B-CLL cells in niches receive survival signals. In this regard,
differential expression of the proapoptotic gene Noxa in LN
and PB B-CLL cells was recently reported (Smit et al., 2007).
We now show that B-CLL cells isolated from BM or LN express
significantly higher levels of surface-bound MMP-9 than their PB
counterparts, indicating that B-CLL cells acquire more
(pro)MMP-9 when present in lymphoid tissues. Both B-CLL cellsFebruary 17, 2010 ª2010 Elsevier Inc. 169
Figure 7. Schematic Representation of the Survival Pathways
Induced by MMP-9 and VCAM-1
a4b1 integrin mediates survival signals for B-CLL cells by two different path-
ways. When VCAM-1 binds the integrin, PI3-K is activated and phosphorylates
Akt, resulting in upregulation of Bcl-xL. When the hemopexin domain of
(pro)MMP-9 (PEX) interacts with the integrin, in conjunction with CD44v,
a different signaling cascade is initiated, leading to Lyn activation, STAT3
phosphorylation, and Mcl-1 upregulation. The noncatalytic hemopexin domain
is sufficient to induce anti-apoptotic effects in B-CLL cells. This mechanism
operates independently from VCAM-1-induced survival, albeit through ligand-
ing of a4b1 integrin by both molecules.
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regulation, as further confirmed by our experiments using
primary stromal cells. In support of our results,
gene microarray analyses have recently shown that MMP-9 is
dramatically upregulated (>25-fold) upon B-CLL cell culture on
a murine stromal cell line (Edelmann et al., 2008). Consistent
with an elevated MMP-9 expression on B-CLL cells in tissues,
our results also show higher levels of phosphorylated Lyn and
Mcl-1 and viability in BM and LN cells than in their PB counter-
parts. Therefore, the survival pathway that we have identified is
active in the physiopathological context of B-CLL. Localization
in lymphoid tissues may thus provide a means for B-CLL cells
to receive survival stimuli and escape apoptosis, as we show
in our study. In these tissues, (pro)MMP-9 may act as an auto-
crine or paracrine survival factor for B-CLL and, even in the pres-
ence of supra- or equimolar levels of its inhibitor TIMP-1, i.e.,
without any catalytic activity, the anti-apoptotic effect will
persist. Our findings support the recent view that more attention
should be paid to the microenvironment as a new therapeutic
target in B cell malignancies (Burger et al., 2009) and may also
have relevance in solid tumor progression. Increased MMP-9
and/or MMP-2 expression correlates with aggressiveness in
several neoplasias including melanoma and breast, lung, and170 Cancer Cell 17, 160–172, February 17, 2010 ª2010 Elsevier Inc.renal carcinomas (Turpeenniemi-Hujanen, 2005). Elevated
levels of these MMPs are also present in solid tumor microenvi-
ronments and play an important role in angiogenesis and
tumor metastasis (Acuff et al., 2006; Deryugina and Quigley,
2006, 2009; Allavena et al., 2008; Bacac and Stamenkovic,
2008). It is therefore possible that part of this (pro)MMP-9
(or (pro)MMP-2) binds to tumor cells (via integrin/hemopexin
domain) and induces survival pathways, as we demonstrate for
B-CLL. As dual and unexpected roles for MMPs in cancer are
now becoming evident (Lo´pez-Otı´n and Matrisian, 2007), our
results reveal new properties for proMMP-9 and highlight the
role of its hemopexin domain in the pathology of B-CLL. Thus,
MMP-9 not only regulates the migration/arrest of B-CLL cells,
but also maintains the malignant population by providing survival
signals. The anti-apoptotic pathway identified here should help
designing future therapies targeting the MMP-9 hemopexin
domain aimed to prevent B-CLL progression.
EXPERIMENTAL PROCEDURES
Patients and Cells
Approval was obtained from the review boards of the Hospital Clı´nico Univer-
sitario, Valencia, and the Hospital Universitario Puerta de Hierro, Madrid, for
these studies. PB samples from 35 B-CLL patients (Table 1) were obtained
after informed consent. BM and LN samples were obtained from four and
two of these patients, respectively (Table 1). CD5+ B-lymphocytes were puri-
fied by Ficoll-Hypaque (Nycomed) centrifugation and negative selection with
anti-CD3-conjugated Dynabeads (Dynal Biotech ASA). The resulting B cell
population was >95% CD19+ and >90% CD5+, determined on a Coulter Epics
XL flow cytometer (Beckman Coulter) with the Expo 32 ADC software (Applied
Cytometry System). Stromal cells were obtained from the mononuclear cell
fraction of one B-CLL patient after 3 week culture in IMDM (GIBCO)/15%
FBS, and used for up to 4 weeks.
Cell Adhesion Assays and Binding Assays in Solution
Adhesion assays were performed on 96-well plates coated with 0.5% BSA,
60 nM proMMP-9 or proMMP-9 variants, or 60 nM VCAM-1. 2 3 105 B-CLL
cells were incubated with 1.4 ng/ml 20,70-bis(carboxyethyl)-5(60)-carboxyfluor-
escein-acetoxymethyl ester (Molecular Probes) for 20 min, suspended in RPMI
1640/0.5% BSA (adhesion medium), and added to the coated wells. After
90 min at 37C, attached cells were lysed with PBS/0.1% SDS and quantified
using a fluorescence analyzer (BMG Labtechnologies). For binding assays in
solution, 105 cells were incubated in 100 ml adhesion medium (for determina-
tion of constitutive proMMP-9 expression) or medium containing proMMP-9 or
rproMMP-9 variants (all at 60 nM) for 30 min at 4C. After washing with ice-cold
RPMI, cells were incubated with anti-MMP-9 pAbs (30 min, 4C), washed with
cold PBS, and incubated (30 min, 4C) with Alexa 488-labeled secondary Abs.
Surface-bound proMMP-9 was analyzed by flow cytometry.
Analysis of Apoptosis
A total of 105 B-CLL cells in 100 ml RPMI/0.1% FCS were added to 96-well
plates coated with either 0.5% BSA, a primary stromal cell monolayer, or
appropriate proteins (all at 60 nM). After 24–48 hr, cells were collected and
resuspended in 13 binding buffer (Bender Medsystems) containing 3 ml of
FITC-Annexin V and 50 mg of propidium iodide. After 10 min, cells were
analyzed by flow cytometry. Cell viability was also analyzed after 48 hr by add-
ing 100 mg MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazoliumbromide)
(Sigma-Aldrich) and additional incubation for 3 hr in the dark. The blue MTT
formazan precipitate was dissolved in 2% SDS (4 hr, room temperature) and
the absorbance at 540 nm was determined on a Multiskan Bichromatic micro-
plate reader (Labsystems). For inhibition experiments, cells in adhesion
medium were incubated (30 min, 37C) with appropriate Abs (10 mg/ml) or
peptides (500 mg/ml) or with LY294002 (2.5 mM), dasatinib (0.1 and 1 mM),
imatinib, nilotinib (1 and 5 mM each), SB203580, Bis I, UO126, PP2, or PP3
(all at 5 mM) prior to seeding into the wells. The effect of soluble proMMP-9
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without (pro)MMP-9 proteins for 48 hr. The presence of proMMP-9 at the
cell surface at this time was confirmed by flow cytometry as described.
Streptavidin-Conjugated Beads DNA Pull-down Assay
Binding of STAT3 to the Mcl-1 promoter was assayed by streptavidin-conju-
gated beads as described previously (Deng et al., 2003, 2006). The following
biotinylated 22 nucleotide sequences were used: 50-CCCTTTTATGGGAA
TACTTTTT-30, containing the specific binding site for STAT factors in the
Mcl-1 promoter (Moshynska et al., 2004), and 50-CCCTTAAGTGGGAATA
CTTTTT-30, a mutated sequence that precludes binding to the promoter.
The 22 nucleotide sequence 50-AGAGTGGTCACTACCCCCTCTG-30, which
does not contain any known enhancer element, was included as a negative
control. All biotin-labeled double strand DNA probes were synthetized by
Sigma-Aldrich. 3 3 107 B-CLL cells were cultured on BSA or proMMP-9 for
2 hr and lysed (5 min, 4C) with buffer A (10 mM HEPES [pH 8.0], 1.5 mM
MgCl2, 200 mM sucrose, 0.5% Nonidet P-40, 10 mM KCl, 0.5 mM dithiotreitol,
and 1 mM EGTA) containing phosphatase and protease inhibitors. The
released crude nuclei were collected by microcentrifugation, washed twice
with buffer A, and resuspended in buffer B (PBS [pH 7.4], 1.0 mM EDTA,
1.0 mM dithiotreitol, and inhibitors). Nuclei were disrupted by sonication at
4C, and debris was removed by centrifugation. Nuclear proteins were then
mixed with 4 mg biotinylated DNA probes and 40 ml streptavidin magnetic parti-
cles (Roche) for 1 hr at room temperature, with shaking. DNA-bound transac-
tivators were dissociated after washing and analyzed by western blotting.
Additional experimental procedures are available as Supplemental
Information.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2009.12.044.
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